Which has higher valuation & earnings, ADAG or CYRX?

CryoPort has higher revenue and earnings than Adagene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 21.38 -$17.61M N/A N/A CryoPort $176.18M 4.72 $78.30M $1.35 12.22

Which has stronger valuation & earnings, ALLO or ADAG?

Adagene has higher revenue and earnings than Allogene Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Allogene Therapeutics $20K 34,515.00 -$190.89M -$0.77 N/A Adagene $7.67M 21.38 -$17.61M N/A N/A

Is ALLO or ADAG more profitable?

Adagene's return on equity of 0.00% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -56.45% -40.36% Adagene N/A N/A N/A

Which has better earnings and valuation, DSGN or ADAG?

Adagene has higher revenue and earnings than Design Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Design Therapeutics N/A N/A -$69.79M -$1.20 N/A Adagene $7.67M 21.38 -$17.61M N/A N/A

Is DSGN or ADAG more profitable?

Adagene's return on equity of 0.00% beat Design Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Design Therapeutics N/A -33.07% -31.29% Adagene N/A N/A N/A

Which has preferable earnings and valuation, ADAG or SLDB?

Adagene has higher revenue and earnings than Solid Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 21.38 -$17.61M N/A N/A Solid Biosciences N/A N/A -$174.32M -$1.95 N/A

Is ADAG or SLDB more profitable?

Adagene's return on equity of 0.00% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Solid Biosciences N/A -73.42% -61.13%

Do analysts prefer ADAG or AVTE?

Adagene currently has a consensus target price of $8.00, indicating a potential upside of 131.21%. Given Adagene's stronger consensus rating and higher possible upside, equities analysts clearly believe Adagene is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adagene 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, ADAG or AVTE?

Adagene has higher revenue and earnings than Aerovate Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 21.38 -$17.61M N/A N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is ADAG or AVTE more profitable?

Adagene's return on equity of 0.00% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Aerovate Therapeutics N/A -90.19% -77.47%

Adagene (ADAG) Competitors

$3.46 +0.07 (+2.06%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$3.46 0.00 (0.00%)

As of 06/3/2026 04:20 PM Eastern

Compare

ADAG vs. CYRX, ALLO, DSGN, SLDB, and AVTE

Should you buy Adagene stock or one of its competitors? MarketBeat compares Adagene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adagene include CryoPort (CYRX), Allogene Therapeutics (ALLO), Design Therapeutics (DSGN), Solid Biosciences (SLDB), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical products" industry.

How does Adagene compare to CryoPort?

Adagene (NASDAQ:ADAG) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Adagene has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, CryoPort has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market.

Adagene presently has a consensus price target of $8.00, suggesting a potential upside of 131.21%. CryoPort has a consensus price target of $15.31, suggesting a potential downside of 7.20%. Given Adagene's stronger consensus rating and higher probable upside, analysts plainly believe Adagene is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
CryoPort	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

9.5% of Adagene shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 21.2% of Adagene shares are held by insiders. Comparatively, 10.0% of CryoPort shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Adagene and Adagene both had 1 articles in the media. CryoPort's average media sentiment score of 1.89 beat Adagene's score of 0.44 indicating that CryoPort is being referred to more favorably in the news media.

Company	Overall Sentiment
Adagene	Neutral
CryoPort	Very Positive

CryoPort has a net margin of 41.57% compared to Adagene's net margin of 0.00%. Adagene's return on equity of 0.00% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
CryoPort	41.57%	-7.92%	-4.79%

CryoPort has higher revenue and earnings than Adagene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	21.38	-$17.61M	N/A	N/A
CryoPort	$176.18M	4.72	$78.30M	$1.35	12.22

Summary

Adagene and CryoPort tied by winning 7 of the 14 factors compared between the two stocks.

How does Adagene compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

In the previous week, Allogene Therapeutics had 3 more articles in the media than Adagene. MarketBeat recorded 4 mentions for Allogene Therapeutics and 1 mentions for Adagene. Allogene Therapeutics' average media sentiment score of 0.53 beat Adagene's score of 0.44 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Allogene Therapeutics	Positive
Adagene	Neutral

Adagene has higher revenue and earnings than Allogene Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	34,515.00	-$190.89M	-$0.77	N/A
Adagene	$7.67M	21.38	-$17.61M	N/A	N/A

Adagene's return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Adagene	N/A	N/A	N/A

Allogene Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Adagene has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

Allogene Therapeutics presently has a consensus price target of $8.52, indicating a potential upside of 326.11%. Adagene has a consensus price target of $8.00, indicating a potential upside of 131.21%. Given Allogene Therapeutics' higher probable upside, equities analysts plainly believe Allogene Therapeutics is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by insiders. Comparatively, 21.2% of Adagene shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Adagene beats Allogene Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Adagene compare to Design Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

Adagene has higher revenue and earnings than Design Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Adagene	$7.67M	21.38	-$17.61M	N/A	N/A

In the previous week, Design Therapeutics had 1 more articles in the media than Adagene. MarketBeat recorded 2 mentions for Design Therapeutics and 1 mentions for Adagene. Design Therapeutics' average media sentiment score of 0.94 beat Adagene's score of 0.44 indicating that Design Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Design Therapeutics	Positive
Adagene	Neutral

Adagene's return on equity of 0.00% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Adagene	N/A	N/A	N/A

Design Therapeutics has a beta of 1.63, meaning that its share price is 63% more volatile than the broader market. Comparatively, Adagene has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

Design Therapeutics currently has a consensus target price of $16.50, indicating a potential upside of 58.05%. Adagene has a consensus target price of $8.00, indicating a potential upside of 131.21%. Given Adagene's stronger consensus rating and higher possible upside, analysts clearly believe Adagene is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 17.1% of Design Therapeutics shares are owned by company insiders. Comparatively, 21.2% of Adagene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Adagene beats Design Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Adagene compare to Solid Biosciences?

Adagene (NASDAQ:ADAG) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Adagene currently has a consensus price target of $8.00, indicating a potential upside of 131.21%. Solid Biosciences has a consensus price target of $16.82, indicating a potential upside of 145.52%. Given Solid Biosciences' higher probable upside, analysts plainly believe Solid Biosciences is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Adagene has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.43, meaning that its share price is 143% more volatile than the broader market.

Adagene has higher revenue and earnings than Solid Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	21.38	-$17.61M	N/A	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

9.5% of Adagene shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 21.2% of Adagene shares are held by insiders. Comparatively, 2.7% of Solid Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Solid Biosciences had 3 more articles in the media than Adagene. MarketBeat recorded 4 mentions for Solid Biosciences and 1 mentions for Adagene. Solid Biosciences' average media sentiment score of 0.72 beat Adagene's score of 0.44 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Adagene	Neutral
Solid Biosciences	Positive

Adagene's return on equity of 0.00% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Solid Biosciences	N/A	-73.42%	-61.13%

Summary

Adagene beats Solid Biosciences on 7 of the 13 factors compared between the two stocks.

How does Adagene compare to Aerovate Therapeutics?

Adagene (NASDAQ:ADAG) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

Adagene's return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Aerovate Therapeutics	N/A	-90.19%	-77.47%

9.5% of Adagene shares are owned by institutional investors. 21.2% of Adagene shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Adagene has higher revenue and earnings than Aerovate Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	21.38	-$17.61M	N/A	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Adagene has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

Adagene currently has a consensus target price of $8.00, indicating a potential upside of 131.21%. Given Adagene's stronger consensus rating and higher possible upside, equities analysts clearly believe Adagene is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Adagene had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for Adagene and 0 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.67 beat Adagene's score of 0.44 indicating that Aerovate Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Adagene	Neutral
Aerovate Therapeutics	Positive

Summary

Adagene beats Aerovate Therapeutics on 10 of the 13 factors compared between the two stocks.

Get Adagene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADAG vs. The Competition

Export

Metric	Adagene	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$160.64M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	N/A	17.78	22.17	24.18
Price / Sales	21.38	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	4.61	6.63	9.84	6.72
Net Income	-$17.61M	$24.20M	$3.57B	$337.19M
7 Day Performance	-12.18%	-4.39%	-2.46%	-0.74%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	82.11%	45.50%	26.49%	33.10%

Adagene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADAG Adagene	2.0883 of 5 stars	$3.46 +2.1%	$8.00 +131.2%	+67.1%	$160.64M	$7.67M	N/A	260
CYRX CryoPort	3.6007 of 5 stars	$13.96 -0.3%	$14.69 +5.2%	+182.5%	$705.63M	$176.18M	10.34	1,186	Positive News Analyst Forecast
ALLO Allogene Therapeutics	2.5785 of 5 stars	$2.12 +6.0%	$8.52 +302.0%	+48.1%	$690.31M	N/A	N/A	310
DSGN Design Therapeutics	2.7635 of 5 stars	$11.40 +3.9%	$16.50 +44.7%	+160.3%	$685.15M	N/A	N/A	40
SLDB Solid Biosciences	2.7936 of 5 stars	$6.88 +3.9%	$16.36 +137.8%	+95.7%	$651.74M	N/A	N/A	100	Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADAG) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adagene (ADAG) Competitors

ADAG vs. CYRX, ALLO, DSGN, SLDB, and AVTE

How does Adagene compare to CryoPort?

Summary

How does Adagene compare to Allogene Therapeutics?

Summary

How does Adagene compare to Design Therapeutics?

Summary

How does Adagene compare to Solid Biosciences?

Summary

How does Adagene compare to Aerovate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG vs. The Competition

Adagene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adagene (ADAG) Competitors

ADAG vs. CYRX, ALLO, DSGN, SLDB, and AVTE

How does Adagene compare to CryoPort?

Which has more risk and volatility, ADAG or CYRX?

Do analysts prefer ADAG or CYRX?

Do institutionals and insiders hold more shares of ADAG or CYRX?

Does the media prefer ADAG or CYRX?

Is ADAG or CYRX more profitable?

Which has higher valuation & earnings, ADAG or CYRX?

Summary

How does Adagene compare to Allogene Therapeutics?

Does the media prefer ALLO or ADAG?

Which has stronger valuation & earnings, ALLO or ADAG?

Is ALLO or ADAG more profitable?

Which has more risk & volatility, ALLO or ADAG?

Do analysts prefer ALLO or ADAG?

Do institutionals & insiders believe in ALLO or ADAG?

Summary

How does Adagene compare to Design Therapeutics?

Which has better earnings and valuation, DSGN or ADAG?

Does the media prefer DSGN or ADAG?

Is DSGN or ADAG more profitable?

Which has more volatility & risk, DSGN or ADAG?

Do analysts prefer DSGN or ADAG?

Do insiders & institutionals believe in DSGN or ADAG?

Summary

How does Adagene compare to Solid Biosciences?

Do analysts recommend ADAG or SLDB?

Which has more risk & volatility, ADAG or SLDB?

Which has preferable earnings and valuation, ADAG or SLDB?

Do insiders and institutionals have more ownership in ADAG or SLDB?

Does the media favor ADAG or SLDB?

Is ADAG or SLDB more profitable?

Summary

How does Adagene compare to Aerovate Therapeutics?

Is ADAG or AVTE more profitable?

Do institutionals & insiders have more ownership in ADAG or AVTE?

Which has better valuation & earnings, ADAG or AVTE?

Which has more volatility and risk, ADAG or AVTE?

Do analysts prefer ADAG or AVTE?

Does the media refer more to ADAG or AVTE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG vs. The Competition

Adagene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools